Investor Relations
Join the revolution in radiation-free diagnostics. REMS technology, 35+ revenue streams, franchise-ready model. $1.6M Year 1 → $58M Year 5 with 41% EBITDA margin.
Company Overview
Instrument
SAFE Note @ $5M pre-money, 20% discount
Regulation
Reg CF
Minimum
$5,000
TAM
$15B+
Global bone health market (devices + services + supplements)
SAM
$3.2B
US bone screening + monitoring + supplements
SOM
$180M
Year 5 target with 60+ locations + franchise network
2021
Founded BioX Unlimited LLC
2023
First REMS device operational
2024
Opened Strength Lab Plus studio, Naples FL
2024
Siemens Healthineers reseller agreement
2025
6 active locations (5 FL + 1 CA). 40+ providers in pipeline.
2026
Rebranded to Halle Health Co. Angel Round opens.
2028
Round 2 — Exclusive investment pool for Round 1 investors
2030
IPO target — Series A institutional round
By the Numbers
3,000+
Scans Completed
~1,000
Active Clients
30:1–51:1
LTV:CAC
$762.88
Blended ARPC
85-90%
Gross Margin
6
Locations
The Problem
of at-risk patients are never screened for bone density issues
the current standard uses ionizing radiation and measures only density — missing bone quality entirely
average wait time for results with traditional screening methods
Our Solution
REMS uses ultrasound-based technology — completely radiation-free, safe for repeat assessments.
Measures bone density, quality, fragility score, and 5-year fracture risk — all in one 15-minute scan.
Clients walk away with results the same day. No waiting weeks for a report.
Franchise-ready "business in a box" — asset-light expansion through partner network.
Financial Projections
Revenue growing from $1.6M to $58.1M with EBITDA margins expanding from 22% to 41% as the platform scales.
| Metric | Year 1 (2026) | Year 2 (2027) | Year 3 (2028) | Year 4 (2029) | Year 5 (2030) |
|---|---|---|---|---|---|
| Operating Metrics | |||||
| Network Locations | 9 | 26 | 56 | 101 | 171 |
| Annual Scans | 1,315 | 4,800 | 12,000 | 26,400 | 54,000 |
| Active Providers | 10 | 30 | 60 | 100 | 160 |
| Subscribers | 144 | 600 | 1,800 | 4,500 | 10,000 |
| Revenue | |||||
| Direct Scan Revenue | $610K | $2.2M | $5.6M | $12.2M | $25.1M |
| Subscriptions | $120K | $480K | $1.4M | $3.6M | $8.0M |
| Provider Network | $394K | $1.2M | $2.5M | $4.2M | $7.2M |
| Franchise Revenue | $293K | $986K | $2.2M | $4.2M | $7.4M |
| Marketplace | $85K | $340K | $900K | $2.1M | $4.5M |
| Affiliate & Partners | $65K | $250K | $600K | $1.2M | $2.4M |
| Content Platform | $12K | $60K | $200K | $500K | $1.2M |
| Waitlist & Events | $25K | $80K | $200K | $450K | $900K |
| Other | $0 | $50K | $200K | $600K | $1.5M |
| Total Revenue | $1.6M | $5.7M | $13.8M | $29.1M | $58.1M |
| Expenses | |||||
| COGS | $561K | $1.8M | $4.0M | $8.1M | $15.1M |
| Technology | $241K | $795K | $1.5M | $2.6M | $4.7M |
| Marketing | $257K | $908K | $2.1M | $4.1M | $7.6M |
| Operations | $192K | $681K | $1.7M | $3.5M | $7.0M |
| Total Expenses | $1.3M | $4.2M | $10.3M | $18.3M | $34.3M |
| EBITDA | $353K | $1.5M | $3.6M | $10.8M | $23.8M |
| EBITDA Margin | 22% | 26% | 26% | 37% | 41% |
Growth Trajectory
| Year | Q1 | Q2 | Q3 | Q4 | Annual | YoY |
|---|---|---|---|---|---|---|
| Year 1 (2026) | $195K | $310K | $420K | $540K | $1.5M | — |
| Year 2 (2027) | $620K | $750K | $870K | $1.0M | $3.2M | 121% |
| Year 3 (2028) | $1.1M | $1.3M | $1.5M | $1.7M | $5.6M | 73% |
| Year 4 (2029) | $1.9M | $2.1M | $2.4M | $2.7M | $9.1M | 62% |
| Year 5 (2030) | $2.9M | $3.3M | $3.7M | $4.1M | $14.0M | 55% |
Total Clients
Locations
Active Providers
Subscribers
Countries
Vendors
Monthly Rev (Dec)
Rev / Employee
Franchise Model
Scalable franchise model enabling rapid geographic expansion without capital-heavy owned locations. Each franchise generates ~$98K/yr for Hallē.
Setup Deposit
$30K
One-time franchise fee
Monthly Fee
$99
Platform access fee
Revenue Share
30%
Of scan revenue
Annual to Hallē
$98K
Per franchise per year
Avg Scans/mo
40
Avg Scan Price
$464
Monthly Gross
$18,560
Hallē Monthly
$5,667
| Period | New | Total | Setup Deposits | Platform Fees | Rev Share | Total Revenue |
|---|---|---|---|---|---|---|
| Year 1 | 3 | 3 | $90K | $4K | $200K | $293K |
| Year 2 | 8 | 11 | $240K | $13K | $733K | $986K |
| Year 3 | 15 | 26 | $450K | $31K | $1.7M | $2.2M |
| Year 4 | 25 | 51 | $750K | $61K | $3.4M | $4.2M |
| Year 5 | 40 | 91 | $1.2M | $108K | $6.1M | $7.4M |
| Year 7 | 80 | 211 | $2.4M | $251K | $14.1M | $16.7M |
| Year 10 | 150 | 511 | $4.5M | $607K | $34.0M | $39.1M |
Unit Economics
Industry-leading customer economics powered by organic acquisition, a waitlist-to-scan engine, and high lifetime value from multi-product engagement.
Weighted Avg Scan
$464.20
80% Bundle ($499) / 20% Full Picture ($325)
Blended ARPC
$762.88
Annual Revenue Per Client across all channels
CAC
$45–75
Customer acquisition cost via digital + waitlist engine
LTV (3yr)
$2,289+
Lifetime value: 4 scans × $430 + subs + marketplace
LTV:CAC
30:1 – 51:1
Industry-leading ratio driven by organic acquisition
Gross Margin
85-90%
Per location (day-rental model, ~$100/day)
Break-Even
1 scan/day
Single scan covers daily location rental cost
Payback
<1 month
CAC recovered on first scan visit
Our proprietary acquisition model converts local demand into booked scans. Clients join a $25 waitlist in their area. When 45 people sign up, we trigger a pop-up scanning event. 80% convert from waitlist to scan, and 15% upgrade to annual monitoring plans.
80%
Waitlist → Scan
15%
Scan → Annual
B2C Economics
$464.20
Weighted avg scan price (80% bundle / 20% basic)
B2B Economics
$98K/yr
Revenue per franchise license ($30K setup + $99/mo + 30% rev share)
Location Economics
$100/day
Rental cost — 1 scan/day = break-even, 85-90% gross margin
Competitive Landscape
The only platform combining radiation-free REMS scanning with a full consumer wellness ecosystem — marketplace, provider network, franchise model, and annual monitoring.
| Company | Technology | No Radiation | Bone Quality | Platform | Pricing |
|---|---|---|---|---|---|
| hallē health | REMS (Echolight) | $325–$499 + subs | |||
| Hologic (DEXA) | Dual X-ray | $100–350 (insurance) | |||
| GE Healthcare | DEXA | $100–350 (insurance) | |||
| BeamMed (Sunlight) | Quantitative US | $50–150 | |||
| BoneForte | REMS (Echolight) | $250–400 | |||
| StrengthX | REMS + BioDensity | $200–350 | |||
| OsteoScan USA | REMS | $250–350 |
Only REMS + Full Platform
No competitor offers REMS scanning + marketplace + subscriptions + provider network + education in one ecosystem
Franchise-Ready Model
Hallē License allows rapid scaling without capital-heavy owned locations — unique in bone health
Multi-Sided Revenue
35+ revenue streams vs competitors with 1-2 streams (scan or hardware sales)
Data Network Effects
Every scan builds the largest radiation-free bone health dataset — AI/ML insights platform moat
NASA + Echolight + Siemens
Partnership ecosystem validates technology and opens enterprise/government channels
Content & Community
Premium education, author platform, and community subscriptions create recurring engagement
Low Fixed Costs
Day-rental model ($100/day) vs. traditional $10K-50K/mo clinic leases = 10x capital efficiency
Global DEXA Device Market
$656.7M (2024)
→ $1.43B (2034)
8.1% CAGR
Bone Density Testing Services
$1.75B (2022)
→ $2.85B (2030)
6.2% CAGR
Bone Health Supplements
$13.8B (2024)
→ $23.1B (2034)
5.3% CAGR
Global Opportunity
A 200M+ at-risk population across 4.6B people, with significant screening gaps in developing markets.
Total Population
4.6B
At Risk
200M+
Target Providers (5yr)
198
Est. Revenue (10yr)
$15.4M
| Country | Pop (M) | Over 50 (M) | DXA/1M | Clinics | Prevalence | Maturity | Opportunity | 5yr Target | 10yr Target | Est. Rev (10yr) |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 335 | 120 | 25-30 | 50,000+ | 10M diagnosed / 44M at risk | Mature | HIGH | 50 | 200 | $13.3M |
| Canada | 40 | 14 | ~20 | 5,000+ | 2.3M affected | Mature | HIGH | 10 | 40 | $2.7M |
| United Kingdom | 67 | 24 | 11-15 | 8,000+ | 3.5M affected | Mature | HIGH | 15 | 120 | $8.0M |
| Germany | 84 | 32 | 15-20 | 12,000+ | 6.3M affected | Mature | MODERATE | 12 | 120 | $8.0M |
| Italy | 59 | 23 | 15-20 | 10,000+ | 5M affected (Echolight HQ) | Mature | HIGH | 10 | 120 | $8.0M |
| Japan | 125 | 52 | 12-18 | 15,000+ | 13M affected | Mature | HIGH | 15 | 60 | $4.0M |
| Australia | 26 | 9 | 20-25 | 4,000+ | 1.2M affected | Mature | HIGH | 8 | 30 | $2.0M |
| South Korea | 52 | 18 | 15-24 | 8,000+ | 5M at risk | Mature | MODERATE | 10 | 60 | $4.0M |
| UAE | 10 | 2 | 5-10 | 1,500+ | Growing awareness | Emerging | HIGH | 8 | 40 | $2.7M |
| Saudi Arabia | 36 | 8 | 3-8 | 2,000+ | 6M at risk | Emerging | HIGH | 8 | 40 | $2.7M |
| Brazil | 215 | 55 | 2-5 | 8,000+ | 10M affected | Developing | VERY HIGH | 10 | 50 | $3.3M |
| Mexico | 130 | 30 | 2-4 | 4,000+ | 4M affected | Developing | HIGH | 5 | 50 | $3.3M |
| India | 1,440 | 300 | <1 | 12,000+ | 61M affected | Early | EXTREME | 8 | 40 | $2.7M |
| China | 1,425 | 400 | <1 | 20,000+ | 90M affected | Developing | EXTREME | 8 | 50 | $3.3M |
| Total | 4,592 | 1,181 | 180,000+ | 198 | 660 | $15.4M | ||||
Investment Structure
Our structured investment approach rewards early believers and builds toward a transformative exit.
Round 1
Blind Crowdfunding / SAFE
Who: Open to everyone — accredited and non-accredited investors worldwide
Earliest entry at lowest valuation. 20% discount on next round. Exclusive access to Round 2.
Round 2
Exclusive Investment Pool
Who: Exclusive to Round 1 investors — proportional to initial contribution
8% annual cumulative dividends. Preferred stock with liquidation preference. Pro-rata rights.
Round 3
Institutional Round
Who: VC funds, family offices, angel groups, and accredited individual investors
Board representation potential. Anti-dilution protection. Clear path to IPO.
Investment Calculator
Three scenarios based on compound annual growth rate (CAGR). Hover over the chart to see exact values for each year. Round 1 (Angel/SAFE) does not include dividends.
SAFE (Simple Agreement for Future Equity) • 2026 — 2028 (2 years)
$37K
$48K
$73K
Note how sharply the curves diverge — this illustrates the inherent uncertainty and range of outcomes in early-stage investing.
| Year | Pessimistic (8%) | Average (14%) | Optimistic (24%) |
|---|---|---|---|
| Today | $25,000 | $25,000 | $25,000 |
| Year 1 | $27,000 | $28,500 | $31,000 |
| Year 2 | $29,160 | $32,490 | $38,440 |
| Year 3 | $31,493 | $37,039 | $47,666 |
| Year 4 | $34,012 | $42,224 | $59,105 |
| Year 5 | $36,733 | $48,135 | $73,291 |
| Profit | +$11,733 | +$23,135 | +$48,291 |
Methodology & Assumptions
These projections are illustrative estimates only based on compound annual growth rate modeling. They do not guarantee future performance. Actual results may vary materially. Early-stage investing carries substantial risk including total loss of investment. See Investment Disclaimer for full risk disclosures.
Platform Readiness
Our platform is operational with core services live. Scaling infrastructure is under active development.
Booking System
Online booking with location/service selection, calendar integration
Client Dashboard
Scan results, progress tracking, file storage, visit history
Admin CMS
Content management, location management, user management, email campaigns
Authentication & Security
OTP login, session management, role-based access
SEO & Marketing Automation
GA4, UTM tracking, SEO optimization, schema markup
Marketplace (MVP)
Product listings, vendor management, Stripe Connect payments
Provider Portal
Provider dashboard, patient management, scan results delivery
Subscription Engine
Annual plans, recurring billing, plan management
Education Platform
Articles, courses, video content, author management
Affiliate & Referral System
Tracking, commission calculation, payout management
Franchise Management System
Licensee onboarding, revenue tracking, compliance monitoring
Mobile App
iOS/Android app with booking, results, tracking
AI/ML Insights Engine
Predictive bone health models, personalized recommendations
Telemedicine Integration
Video consultations, remote monitoring, specialist matching
Enterprise B2B Platform
Corporate wellness programs, bulk booking, HR dashboards
Overall platform readiness
~55%
Team & Budget
Scaling from 8 FTE in Year 1 to 80 FTE by Year 5, with payroll growing from $780K to $8.8M as revenue per employee increases.
Year 1 (2026)
8
FTE
$780K
Year 2 (2027)
16
FTE
$1.6M
Year 3 (2028)
30
FTE
$3.2M
Year 4 (2029)
50
FTE
$5.5M
Year 5 (2030)
80
FTE
$8.8M
| Role | Count | Salary Range | Department |
|---|---|---|---|
| CEO / Co-Founder | 1 | $120-150K | Executive |
| CTO / Tech Lead | 1 | $130-160K | Engineering |
| Full-Stack Developer | 1 | $110-140K | Engineering |
| Marketing Director | 1 | $100-120K | Marketing |
| Operations Manager | 1 | $70-90K | Operations |
| Clinical Coordinator | 1 | $60-80K | Clinical |
| Sales Representative | 1 | $55-70K + commission | Sales |
| Customer Success | 1 | $45-60K | Operations |
| Role | Count | Salary Range | Department |
|---|---|---|---|
| VP of Sales | 1 | $120-150K | Sales |
| Sales Representative | 3 | $55-70K + commission | Sales |
| UX/UI Designer | 1 | $90-120K | Engineering |
| Scan Technician | 2 | $45-60K | Clinical |
| Content Manager | 1 | $60-80K | Marketing |
| Role | Count | Salary Range | Department |
|---|---|---|---|
| Regional Manager | 3 | $80-100K | Operations |
| Franchise Support | 2 | $60-80K | Operations |
| Data Engineer | 1 | $120-150K | Engineering |
| Senior Developer | 2 | $130-160K | Engineering |
| Marketing Specialist | 3 | $55-75K | Marketing |
| Scan Technician | 3 | $45-60K | Clinical |
| Role | Count | Salary Range | Department |
|---|---|---|---|
| COO | 1 | $150-200K | Executive |
| VP Marketing | 1 | $120-150K | Marketing |
| International Expansion Lead | 1 | $100-130K | Operations |
| Additional staff across departments | 17 | $50-120K | Various |
| Role | Count | Salary Range | Department |
|---|---|---|---|
| CFO | 1 | $160-220K | Executive |
| VP International | 1 | $130-170K | Operations |
| Additional staff across departments | 28 | $50-130K | Various |
$180K
Y1
$210K
Y2
$250K
Y3
$280K
Y4
$310K
Y5
Leadership
A lean, focused team combining health-tech vision, medical compliance expertise, and AI-powered engineering to scale REMS diagnostics nationally.
Founder & Ideologist
Visionary behind HALLĒ. Conceived the REMS-first approach and drives the mission to make radiation-free bone health accessible to all.
CEO & Medical Compliance
Medical professional overseeing clinical compliance, provider network standards, and FDA regulatory alignment for REMS technology.
Engineering & Product
AI-powered development pipeline building the platform — booking, dashboards, marketplace, provider ecosystem, and analytics.
Legal
Please review the following disclosures carefully before considering any investment.
This page contains forward-looking statements about expected future performance. These are based on current expectations and involve risks and uncertainties. Actual results may differ materially. Revenue projections and return calculations are illustrative only.
Investing in early-stage companies involves substantial risk, including potential loss of your entire investment. Key risks include: limited operating history, dependence on key personnel, regulatory changes, competition, market adoption uncertainty, and general economic conditions.
Information on this page is for informational purposes only and does not constitute an offer to sell or recommendation of any security. Any offering will be made only through official documents filed with or exempt from applicable securities laws.
A SAFE is not equity and does not represent current ownership. SAFEs convert to equity at a future priced round, subject to valuation cap and discount rate. No guarantee that a conversion event will occur. SAFEs have no maturity date, bear no interest, and carry no voting rights.
Securities offerings will comply with applicable federal and state laws, including Reg CF, Reg D 506(b), and 506(c). Certain opportunities may be limited to accredited investors as defined by SEC Rule 501.
Dividend projections are illustrative estimates. Actual dividends depend on profitability, board approval, and cash flow. The company is under no obligation to pay dividends. Past performance does not guarantee future results.
Investor FAQ
A SAFE (Simple Agreement for Future Equity) is the most common instrument for early-stage investing. Your investment converts to equity at the next priced round, typically at a 20% discount to later investors, subject to a $5M valuation cap.
In Round 1, we open a 2-year investment window (2026-2028). When the round closes, each investor's percentage is determined by their contribution relative to the total pool. The larger your contribution, the greater your stake.
Your ownership equals your investment divided by the total angel pool at close. This determines your proportional allocation in Round 2 and equity stake at SAFE conversion. The 20% discount means you get equity at 20% lower valuation than Round 2 investors.
Dividends apply only to Rounds 2 and 3 (8% and 6% respectively). Round 1 (SAFE) does not include dividends. Dividends accrue annually and are paid when profitable and board-approved.
At IPO (targeted 2030), all preferred stock converts to common stock 1:1. Investors can sell on the public market. Early investors benefit from significantly lower entry valuations.
Securities are generally illiquid. Under Reg CF, SAFEs have a 1-year holding period. There is no secondary market. Investors should expect to hold 5-10 years.
Round 1: $5,000 minimum. Round 2: $10,000. Round 3: $50,000. Non-accredited investors in Round 1 are subject to annual limits under Reg CF.
The calculator shows Pessimistic (8%), Average (14%), and Optimistic (24%) CAGR. S&P 500 averages ~10%. Strong health-tech can achieve 15-25%+. Only invest what you can afford to lose.
Join the Future
Join our angel round and become part of the REMS revolution. Early investors receive the most favorable terms and exclusive access to future rounds.
Monetization Map
A diversified revenue model spanning client services, subscriptions, provider network, marketplace, and data licensing. Click any stream for details.
35
Revenue Streams
14
Active Now
9
Categories
Revenue Calculator
Slide to see projected annual revenue across all 7 channels based on number of active clients.
1,000
active clients
Annual Revenue
$865K
ARPC: $864.66
| Channel | Revenue | % of Total |
|---|---|---|
| Scan Services | $464,200 | 53.7% |
| Subscriptions | $134,125 | 15.5% |
| Marketplace | $4,800 | 0.6% |
| Affiliate | $7,000 | 0.8% |
| Provider Network | $246,000 | 28.5% |
| Waitlist & Events | $6,750 | 0.8% |
| Content Platform | $1,788 | 0.2% |
| Total | $864,663 | 100% |
Use of Funds
Every dollar is allocated to accelerate growth, expand our technology platform, and bring REMS bone health scanning to more communities.
Location Expansion
New markets, REMS equipment procurement, facility setup, and geographic expansion.
Technology & Platform
Provider ecosystem, client dashboard, AI analytics, and mobile app development.
Marketing & Acquisition
Brand awareness, digital marketing, SEO, partnerships, and client acquisition.
Team & Operations
Key hires in operations, clinical staff, customer success, and management.
Legal & Reserve
SEC compliance, legal counsel, insurance, licensing, and reserve fund.
